Umbilical Cord Mesenchymal Células madre Therapy for Diabetic Nephropathy

Breve resumen:
This clinical trial assessed the safety of human umbilical cord mesenchymal terapia con células madre en 15 patients with diabetic nephropathy. Fifteen subjects received umbilical cord mesenchymal terapia con células madre 3 times. Approximately 1 × 106/kg of human umbilical cord mesenchymal stem cells were administered by peripheral intravenous infusion once a month .Endpoints:Primary endpoint: Safety and adverse events (safety and tolerability of umbilical cord mesenchymal terapia con células madre within 60 semanas).Secondary endpoint indicators:Efficacy measures: eGFR, urinary albumin-to-creatinine ratio, and percentage changes of 24-h urinary protein quantities from baseline to 60 semanas.


NBScience

organización de contratos de investigación

terapia con células madre